This study investigates the effects of a sequential "lying-sitting-standing" Baduanjin intervention on patients with acute coronary syndrome complicated by heart failure. By evaluating cardiopulmonary function and quality of life through indicators such as echocardiography, NT-proBNP, 6MWT, NYHA classification, and SF-36, we aim to compare its efficacy with conventional treatment. The objective is to provide new insights for early cardiac rehabilitation strategies in patients with acute coronary syndrome complicated by heart failure
Age range
85 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Patients were stratified based on their 6-minute walk test distance
Timeframe: From enrollment to the end of the 12-week treatment
NYHA(New York Heart Association)classification of cardiac function
Timeframe: From enrollment to the end of the 12-week treatment
Left ventricular ejection fraction (LVEF) on echocardiography
Timeframe: From enrollment to the end of the 12-week treatment
C-reactive protein levels
Timeframe: From enrollment to the end of the 12-week treatment
SF-36(ShortForm36HealthSurvey)
Timeframe: From enrollment to the end of the 12-week treatment
NT-proBNP(N-terminal pro-B-type natriuretic peptide)levels
Timeframe: From enrollment to the end of the 12-week treatment
FMD(flow-mediated vasodilation)
Timeframe: From enrollment to the end of the 12-week treatment
ADL(Activities of Daily Living Scale)
Timeframe: From enrollment to the end of the 12-week treatment